Mir Sohail Fazeli

Dr. Mir Sohail Fazeli

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2021 in Clinical and Experimental Rheumatology
Verified
Journal Article
Closed access
MFMir Sohail Fazeli
Mir Sohail Fazeli
VKVadim Khaychuk
Vadim Khaychuk
KWKeith Wittstock
Keith Wittstock
XHXue Han
Xue Han
GCGrace Crocket
Grace Crocket
LFLeticia Ferri
Leticia Ferri
Reviews; Authors: M.S. Fazeli, V. Khaychuk, K. Wittstock, X. Han, G. Crocket, M. Lin, S.L. Hill, L. Ferri

21 November 2022 in Journal of Medical Internet Research
Verified
Journal Article
Open access
CGChristine C Guo
Christine C Guo
PCPatrizia Andrea Chiesa
Patrizia Andrea Chiesa
CMCarl de Moor
Carl de Moor
MFMir Sohail Fazeli
Mir Sohail Fazeli
TSThomas Schofield
Thomas Schofield
ASAlf Scotland
Alf Scotland
Background: With the advent of smart sensing technology, mobile and wearable devices can provide continuous and objective monitoring and assessment of motor function outcomes. Objective: We aimed to describe the existing scientific literature on wearable and mobile technologies that are being used or tested for assessing motor functions in mobility-impaired and healthy adults and to evaluate the degree to which these devices provide clinically valid measures of motor function in these populations. Methods: A systematic literature review was conducted by searching Embase, MEDLINE, CENTRAL (January 1, 2015, to June 24, 2020), the United States and European Union clinical trial registries, and the United States Food and Drug Administration website using predefined study selection criteria. Study selection, data extraction, and quality assessment were performed by 2 independent reviewers. Results: A total of 91 publications representing 87 unique studies were included. The most represented clinical conditions were Parkinson disease (n=51 studies), followed by stroke (n=5), Huntington disease (n=5), and multiple sclerosis (n=2). A total of 42 motion-detecting devices were identified, and the majority (n=27, 64%) were created for the purpose of health care–related data collection, although approximately 25% were personal electronic devices (eg, smartphones and watches) and 11% were entertainment consoles (eg, Microsoft Kinect or Xbox and Nintendo Wii). The primary motion outcomes were related to gait (n=30), gross motor movements (n=25), and fine motor movements (n=23). As a group, sensor-derived motion data showed a mean sensitivity of 0.83 (SD 7.27), a mean specificity of 0.84 (SD 15.40), a mean accuracy of 0.90 (SD 5.87) in discriminating between diseased individuals and healthy controls, and a mean Pearson r validity coefficient of 0.52 (SD 0.22) relative to clinical measures. We did not find significant differences in the degree of validity between in-laboratory and at-home sensor-based assessments nor between device class (ie, health care–related device, personal electronic devices, and entertainment consoles). Conclusions: Sensor-derived motion data can be leveraged to classify and quantify disease status for a variety of neurological conditions. However, most of the recent research on digital clinical measures is derived from proof-of-concept studies with considerable variation in methodological approaches, and much of the reviewed literature has focused on clinical validation, with less than one-quarter of the studies performing analytical validation. Overall, future research is crucially needed to further consolidate that sensor-derived motion data may lead to the development of robust and transformative digital measurements intended to predict, diagnose, and quantify neurological disease state and its longitudinal change.

14 June 2021 in The European Journal of Health Economics
Verified
Journal Article
Open access
PDF file
MPMir-Masoud Pourrahmat
Mir-Masoud Pourrahmat
AKAshley Kim
Ashley Kim
AKAnuraag R. Kansal
Anuraag R. Kansal
MHMarg Hux
Marg Hux
DPDivya Pushkarna
Divya Pushkarna
KCKaren C. Chung
Karen C. Chung
Objectives: Cancer diagnoses at later stages are associated with a decrease in health-related quality of life (HRQOL). Health state utility values (HSUVs) reflect preference-based HRQOL and can vary based on cancer type, stage, treatment, and disease progression. Detecting and treating cancer at earlier stages may lead to improved HRQOL, which is important for value assessments. We describe published HSUVs by cancer type and stage. Methods: A systematic review was conducted using Embase, MEDLINE®, EconLit, and gray literature to identify studies published from January 1999 to September 2019 that reported HSUVs by cancer type and stage. Disutility values were calculated from differences in reported HSUVs across cancer stages. Results: From 13,872 publications, 27 were eligible for evidence synthesis. The most frequent cancer types were breast (n = 9), lung (n = 5), colorectal (n = 4), and cervical cancer (n = 3). Mean HSUVs decreased with increased cancer stage, with consistently lower values seen in stage IV or later-stage cancer across studies (e.g., − 0.74, − 0.44, and − 0.51 for breast, colorectal, and cervical cancer, respectively). Disutility values were highest between later-stage (metastatic or stage IV) cancers compared to earlier-stage (localized or stage I–III) cancers. Conclusions: This study provides a summary of HSUVs across different cancer types and stages that can inform economic evaluations. Despite the large variation in HSUVs overall, a consistent decline in HSUVs can be seen in the later stages, including stage IV. These findings indicate substantial impairment on individuals’ quality of life and suggest value in early detection and intervention.

3 April 2023 in Journal of Workplace Behavioral Health
Verified
Journal Article
Open access
JHJuliet Herbert
Juliet Herbert
LFLeticia Ferri
Leticia Ferri
BHBrenda Hernandez
Brenda Hernandez
IZIsaias Zamarripa
Isaias Zamarripa
KHKimberly Hofer
Kimberly Hofer
KAKald Abdallah
Kald Abdallah
Up to half of the population have introverted personalities. Workplace diversity can lead to increased productivity, creativity and problem-solving. Understanding introversion in relation to workplace performance and creativity and how to encourage inclusion of introverts would benefit employers and employees. We describe the evidence defining and evaluating introversion, prevalence of introversion across groups, and strategies for promoting workplace inclusion of introverts. We searched MEDLINE®, Embase, and PsycINFO up to February 11, 2021. Of 2,724 records, 21 studies were included. Introversion definitions were generally negative and dated. Robust prevalence data were unavailable, and no studies aimed to test strategies for promoting workplace inclusion of introversion. Nevertheless, literature suggests that employees who identify with modern definitions of introversion may benefit from individualized workplace strategies such as flexible working environments, work/home-life boundaries, varied team composition, provision of social support, and relaxation training. Further empirical studies in the industrial setting with robust designs using modernized personality definitions are warranted to support the development of effective strategies to increase inclusion of different personalities in the workplace.

1 December 2020 in Journal of Clinical Epidemiology
Verified
Journal Article
Closed access
MJMaya M. Jeyaraman
Maya M. Jeyaraman
RRRasheda Rabbani
Rasheda Rabbani
LCLeslie Copstein
Leslie Copstein
RRReid C. Robson
Reid C. Robson
NANameer Al-Yousif
Nameer Al-Yousif
AAAhmed M. Abou-Setta
Ahmed M. Abou-Setta

31 January 2022 in Therapeutic Advances in Musculoskeletal Disease
Verified
Journal Article
Open access
MFMir Sohail Fazeli
Mir Sohail Fazeli
LMLouis McIntyre
Louis McIntyre
YHYili Huang
Yili Huang
XCXavier Chevalier
Xavier Chevalier
Knee osteoarthritis (KOA) is a debilitating disease characterized by chronic pain, stiffness, and decreased mobility. Intra-articular injectable therapies show good clinical efficacy in improving symptoms; however, these therapies and their comparators (intra-articular saline) have been associated with a large underlying placebo effect. We aimed to describe the existing evidence on the challenges, hypotheses, and potential solutions to mitigate the intra-articular placebo effect in clinical trials in KOA. A targeted literature review was conducted by searching Embase, MEDLINE®, and CENTRAL using predefined study selection criteria. All eligible studies identified were extracted for relevant data, and results were narratively summarized. Forty-three studies were included following screening. Challenges associated with the intra-articular placebo effect included its ability to mask the comparative efficacy of active treatments in trials ( n = 7 studies), long-lasting effects (up to 6 months; n = 3), and substantial variation of placebo effect sizes across populations ( n = 3). Hypotheses for the mechanism of the placebo effect included aspiration of synovial fluid during administration ( n = 6) and dilution of inflammatory mediators ( n = 2). Factors affecting the placebo effect size were more invasive routes of administration (e.g., injection versus oral; n = 4) and patient expectations ( n = 2). Proposed solutions included the suggestion for readers to weigh the relevance of clinical trial evidence against the presence of large underlying placebo effects ( n = 9), discontinuation of intra-articular saline as an appropriate placebo ( n = 5), and inclusion of ‘no treatment’ or sham injection as a control ( n = 4). The intra-articular placebo effect is a well-documented occurrence in KOA clinical trials, and it is suggested that it be accounted for when designing randomized controlled trials. Awareness and understanding of the intra-articular placebo effect in KOA are required for fair interpretation of clinical trial evidence.